QNCX
NASDAQQuince Therapeutics Inc.
News25/Ratings7
News · 26 weeks49+100%
2026-03-012026-08-23
Mix2890d
- SEC Filings14(50%)
- Other5(18%)
- Insider4(14%)
- Analyst4(14%)
- Leadership1(4%)
Latest news
25 items- SECSEC Form DEF 14A filed by Quince Therapeutics Inc.DEF 14A - Quince Therapeutics, Inc. (0001662774) (Filer)
- SECSEC Form EFFECT filed by Quince Therapeutics Inc.EFFECT - Quince Therapeutics, Inc. (0001662774) (Filer)
- ANALYSTCraig Hallum initiated coverage on Quince Therapeutics with a new price targetCraig Hallum initiated coverage of Quince Therapeutics with a rating of Buy and set a new price target of $68.00
- SECQuince Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - Quince Therapeutics, Inc. (0001662774) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Quince Therapeutics Inc.SCHEDULE 13G/A - Quince Therapeutics, Inc. (0001662774) (Subject)
- SECSEC Form SCHEDULE 13G filed by Quince Therapeutics Inc.SCHEDULE 13G - Quince Therapeutics, Inc. (0001662774) (Subject)
- SECQuince Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Quince Therapeutics, Inc. (0001662774) (Filer)
- PRQuince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate UpdateCompleted acquisition of Orphai Therapeutics, adding LAM-001, an inhaled formulation of rapamycin for the treatment of multiple serious, underserved pulmonary diseases, to pipeline LAM-001 Phase 2b data in PH-ILD anticipated in the first quarter of 2028; Phase 2 data in BOS anticipated in the first quarter of 2027 Closed private placement financing, receiving $115 million in upfront gross proceeds, with potential for up to an additional $83 million upon exercise of warrants (including warrants issued to former Orphai stockholders) Cash and cash equivalents of $116 million as of June 30, 2026, expected to fund operations through the end of 2028 SOUTH SAN FRANCISCO, Calif., Aug. 14, 2026
- SECSEC Form SCHEDULE 13G filed by Quince Therapeutics Inc.SCHEDULE 13G - Quince Therapeutics, Inc. (0001662774) (Subject)
- SECAmendment: SEC Form S-3/A filed by Quince Therapeutics Inc.S-3/A - Quince Therapeutics, Inc. (0001662774) (Filer)
- SECQuince Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - Quince Therapeutics, Inc. (0001662774) (Filer)
- SECSEC Form PRE 14A filed by Quince Therapeutics Inc.PRE 14A - Quince Therapeutics, Inc. (0001662774) (Filer)
- SECSEC Form S-3 filed by Quince Therapeutics Inc.S-3 - Quince Therapeutics, Inc. (0001662774) (Filer)
- SECAmendment: Quince Therapeutics Inc. filed SEC Form 8-K: Financial Statements and Exhibits8-K/A - Quince Therapeutics, Inc. (0001662774) (Filer)
- ANALYSTOppenheimer initiated coverage on Quince Therapeutics with a new price targetOppenheimer initiated coverage of Quince Therapeutics with a rating of Outperform and set a new price target of $82.00
- PRQuince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory BoardSOUTH SAN FRANCISCO, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (NASDAQ:QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious underserved diseases, today announced the formation of a Scientific Advisory Board (SAB) of leading clinicians to support the advancement of LAM-001, an inhaled formulation of rapamycin (mTOR inhibitor) designed to enhance pulmonary delivery and reduce systemic exposure. Comprised of internationally recognized experts in pulmonary medicine, the SAB will be instrumental in progressing the development of LAM-001 across multiple pulmonary indications including pulmonary h
- SECAmendment: Quince Therapeutics Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders8-K/A - Quince Therapeutics, Inc. (0001662774) (Filer)
- SECQuince Therapeutics Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders8-K - Quince Therapeutics, Inc. (0001662774) (Filer)
- ANALYSTLeerink Partners initiated coverage on Quince Therapeutics with a new price targetLeerink Partners initiated coverage of Quince Therapeutics with a rating of Outperform and set a new price target of $4.00
- ANALYSTCantor Fitzgerald initiated coverage on Quince Therapeutics with a new price targetCantor Fitzgerald initiated coverage of Quince Therapeutics with a rating of Overweight and set a new price target of $4.00
- INSIDERSEC Form 4 filed by Director Lamond David4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
- INSIDERSEC Form 4 filed by Director Senner Christopher J.4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
- INSIDERSEC Form 4 filed by Chief Corp. Affairs Officer Roberts Brigette4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
- INSIDERSEC Form 3 filed by new insider Roberts Brigette3 - Quince Therapeutics, Inc. (0001662774) (Issuer)
- SECSEC Form 8-K filed by Quince Therapeutics Inc.8-K - Quince Therapeutics, Inc. (0001662774) (Filer)
QNCX FAQ
6 questionsWhere does QNCX stock trade?
Quince Therapeutics Inc. (QNCX) is listed on NASDAQ.What sector and industry is QNCX in?
Quince Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Quince Therapeutics Inc. go public?
Quince Therapeutics Inc. (QNCX) completed its IPO in 2019.What are analysts saying about QNCX?
Quince Therapeutics Inc. has had 7 recent analyst actions on file. The most recent action was from Craig Hallum: Buy on 2026-08-20. Recent price targets range from $400.00 to $1000.00.What companies are similar to QNCX?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare QNCX side-by-side with any of them on Quantisnow.How can I track QNCX on Quantisnow?
Quantisnow aggregates Quince Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow QNCX to receive live email and push alerts on every new disclosure.